Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

This research and development focus offers tremendous potential to identify novel, high-value therapies addressing a wide range of diseases and disorders triggered by inflammation, including asthma and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Amira’s research strategy emphasizes systematic and early evaluation of compounds’ pharmacokinetics, pharmacodynamics and safety, leading to definitive “go-no go” decisions. The efficiency of this research process is enhanced by the discovery team’s unparalleled insights into bioactive lipid pathways and the complex signaling processes that control inflammation.

Amira’s founders were pivotal in the discovery of several high-profile and successful clinical compounds, including Singulair ^®, Arcoxia^®, and Vioxx^®. This track record, combined with Amira’s focus on identifying high-value compounds for targets within the bioactive lipid pathways, has enabled Amira to generate $28 million in funding from its investors and to discover five highly-targeted, novel compounds, since Amira's founding in mid-2005.